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Small molecule libraries play a crucial role in chemical biology, especially, in high-
throughput screening. It leads to discovery of new hit to lead compound that 
potential application in clinical phase. Therefore, library construction strategy is a 
subject for organic chemist. One of the most famous and important trend is 
Diversity-oriented Synthesis (DOS) methodology, which was developed by 
Professor Stuart Schreiber. From the first time introduced, DOS has been proved to 
be an essential tool in the exploration of chemical and biological space. Our 
research group has been working on the development of new DOS pathways and 
library realizations, we proposed a privileged substructure-based diversity-oriented 
synthesis (pDOS) approach for the efficient generation of distinct polyheterocyclic 
core skeletons embedded with privileged structure. Continuation of our work, we 
using pDOS approach for development of new pDOS pathways and construction of 
small compound libraries for high-throughput screening. 
 
In chapter 1, a new privileged substructure-based diversity-oriented synthesis 
(pDOS) pathway for the systematic fabrication of polyheterocyclic molecular 
frameworks with pyrimidine as the key privileged substructure ring have been 
developed. In this study, we established five pathways to achieve different 
 
2 
pyrimidine-embedded core skeletons from a key intermediate ortho-
alkynylpyrimidine carbaldehydes with high molecular diversity and positions with 
potential functionalities for further modification. 
In chapter 2, we describe the practical construction of library using solid-phase 
synthesis with Tetra-Substituted tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-
4,7(6H,8H)-dione as the core privileged substructure. The diversity of this core 
skeleton was expanded by introduction of at four R- substituted diversity points. As 
a result, 81 compound libraries were constructed with provide a potential source of 
for biological screening. 
 
Keywords: Diversity-oriented synthesis, privileged substructure, pyrimidine, 
polyheterocyclic, N-acyliminium, beta-turn, small molecule libraries, solid-phase.   
 




I. Chapter 1 
Development of Novel Pyrimidine-Embedded 
Polyheterocycles Pathways Using Privileged Substructure-
Based Diversity-Oriented Synthesis (pDOS) 
1.1. Introduction 
Diversity-oriented synthesis (DOS) aims to synthesize collections of molecules that 
access the unexplored molecular frameworks with maximum structural and 
stereochemical diversity for biological screening
1,3
. After 14 years from the first 
time introduced in the chemical literature by Professor Stuart Schreiber
2
, DOS has 
been proved to be an essential tool in the exploration of chemical and biological 
space
4-6
. There are many DOS pathways has been developed, it lead to construct of 
small molecule libraries that are widely distributed in chemical space and, as a 




Figure 1: A schematic illustration that compares the synthetic strategies in (A) traditional 
combinatorial chemistry for the construction of a focused library, (B) a DOS pathway driven 
by pure complexity-generating reactions, and (C) the pDOS pathway7
 
 
Privileged structures are important for the efficient discovery of bioactive small 
molecules. Our research group has been working on the development of new DOS 
pathways and library realizations, we proposed a privileged substructure-based 
diversity-oriented synthesis (pDOS) approach for the efficient generation of distinct 
polyheterocyclic core skeletons embedded with privileged structure, which aims to 
emphasize the importance of skeletal diversity through the creative reconstruction 
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of privileged substructures embedded in polyheterocyclic molecular frameworks. 
This is because three-dimensionally discrete core skeletons containing privileged 
substructures are expected to show high affinity with excellent specificity toward 
various biopolymers owing to the natural selection process and the evolutionary 
similarity between gene products
7-16
(figure 1). 
Continuation of our work, we choose pyrimidine as the key privileged substructure 
to develop of novel new pDOS pathways. Pyrimidine is a privileged sub-structural 
motif observed in many bioactive small molecules and drugs such as Antibacterial 




Figure 2: List of pyrimidine and fused pyrimidine marketed drugs 
 
The diversity of scaffold is considered as crucial diversity element, molecule 
libraries that have three-dimensional structure will have more opportunities to 
interact with biomacromolecules (because they are three-dimensional structure 
environments with more or less defined binding regions, pockets, and surfaces, and 
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they will interact only with molecules that have diversity dimensional structure)
19
. 
As pyrimidine, although a large number of pyrimidine-containing bioactive 
compounds are synthesized, their structural frameworks are mainly limited to 
monocyclic or bicyclic skeletons, probably because of the usual design strategy of 
pyrimidine as nucleoside analogs (Figure 3).  
 
Figure 3: A new diversity-oriented synthesis pathway for the fabrication of a pyrimidine-
embedded polyheterocycles library was developed for potential interactions with diverse 
biopolymers25 
 
Herein, we describe a new pDOS strategy for the systematic fabrication of 
polyheterocyclic molecular frameworks with pyrimidine as the key privileged 






1.2. Results and discussion 
 
A new pDOS strategy has been developed for the systematic fabrication of 
polyheterocyclic molecular frameworks around a pyrimidine ring. As shown in 
figure 4, ortho-alkynylpyrimidine carbaldehyde
20
 have been used as a key 
intermediate, which can be easily converted to imines or hydrazones, then converted 
to five different pyrimidine-containing poly heterocycles (A to F) using different 
reaction condition and coupling partner
20-24
 (figure 4). 
 
Figure 4: Diversity-oriented synthesis pathways 
 
4-chloro-6-(methylamino)pyrimidine-5-carbaldehyde react with different alkyne via 
sonogashira coupling to form the key intermediate ortho-alkynylpyrimidine 
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carbaldehyde at a high yield (75-90%) . Then, it was reacted with various amines to 
afford the ortho-alkynylpyrimidyl aldimines, followed by Ag-mediated 6-endo 
cyclization of the imines with the internal alkyne to generate the pyridinium 
intermediates. Pyridinium intermediates are active compound, which is can be easy 
reacted with nucleophile to afford nucleophilic addition products. From here, five 
different pyrimidine-containing poly heterocycles was synthesized18-19.  
To synthesize five different scaffolds, three key intermediate has been prepared by 
Sonogashira coupling reaction, structure as shown in figure 5 (1a-c). 
 
 
Figure 5: Three key intermediates (1c was particular prepared in order to synthesize 
scaffold D and E) 
 
1.2.1. Pathway A 
 
Scheme 1: Preparation of scaffold A 
 
First, for the preparation of pathway A (scaffold A) pyridinium intermediates was 
treated with dialkylmalonates (under base condition) to form nucleophilic addition 
product and subsequent lactamization of the esters with the methylamine moiety at 
the C-4 position of the pyrimidine afforded the pyrimidine-containing tricyclic cores. 
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Then, lactam undergoes tautomerization to form scaffold A. In summary, scaffold A 
was carried out at in good to excellent yields. The results of synthesis of scaffold A 
as shown in table 1. 
Table 1: Exploration of Scaffold A 
Product R1 R2 R3 R4 Yield
a
 (%) 
2a Phenyl 4-Meo-Ph Ethyl Methyl 74 
2b Phenyl 4-Meo-Ph Methyl Methyl 70 
2c Phenyl 2-methoxyethyl Methyl Methyl 97 
2d n-propyl 4-Meo-Ph Ethyl Methyl 84 
2e n-propyl 4-Meo-Ph Methyl Methyl 83 
2f n-propyl 2-methoxyethyl Methyl Methyl 77 
a
Isolated yields 
Scaffold A with four different modifiable substituents at the R1, R2, R3, and R4 
positions and the OH free group are ideally for the DOS’s library construction in 
future. 
1.2.2. Pathway B 
Scheme 2: the preparation of scaffold B and expected mechanism 
 
For the preparation of pathway B (scaffold B) ortho-alkynylpyrimidine 
carbaldehyde 1a and 1b was treated with diaminoalkanes to afford the cyclic aminal 
intermediates, then Iodine was added to convert intermediates into scaffold B via 
tandem cyclization mechanism (Scheme 2). In addition, the Iodo-group is 
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modifiable in the future to expand the molecular diversity via cross coupling 
reaction such as Sonogashira coupling reaction, Suzuki coupling reaction, Heck 
reaction and so on. In this one-pot procedure, iodine play as oxidizing agent for the 
imidazolidine ring formation and also activated the internal alkyne for the 6-
endocyclization. The results of synthesis of scaffold B as shown in table 2. 
Table 2: Exploration of Scaffold B 
Product R1 n Yield
a
 (%) 
3a phenyl 1 60b 
3b n-propyl 1 35c 
3c phenyl 2 57 
3d n-propyl 2 53 
3e phenyl 3 25 
3f n-propyl 3 39 




Fully aromatized product 3h was obtained in 10% yield, 
c
Fully aromatized product 3i was 
obatined in 34% yield 
Due to oxidization condition, compound 3a and 3b was converted into the fully 
aromatized product 3h and 3i in 10% and 34% yield, respectively. 3h and 3i can be 
obtained in more than 60% yield if the reaction was stirred overnight. 
1.2.3. Pathway C 
 
Scheme 3: the preparation of scaffold C 
 
For the preparation of scaffold C, ortho-alkynylpyrimidine carbaldehyde 1a and 1b 
was treated with tosylhydrazine instead of amine to afford hydrazone intermediates 
1h and 1i. Then, it has been converted to pyridinium intermediates via Ag-mediated 
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6-endo cyclization of the hydrazone, followed by 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU)-catalyzed nucleophilic addition of R4-containing terminal alkynes 
Subsequent intramolecular 5-endo cyclization and aromatization afforded scaffold C. 
The results of synthesis of scaffold C was shown in table 3. 
 
Table 3: Exploration of Scaffold C 
Product R1 R4 Yield
a 
4a Phenyl Phenyl 64 
4b Phenyl Cyclopropyl 72 
4c Phenyl 1-methylethenyl 51 
4d n-propyl Phenyl 70 
4e n-propyl cyclopropyl 69 
4f n-propyl 1-methylethenyl 69 
a
Isolated yields 
1.2.4. Pathway D and E 
 
Scaffold D and E sharing the important intermediate 1c (a vinyl group at 
the R1 position of key substrate). 1c, then, was reacted with allylic or homoallylic 
amines to afford ortho-alkynyl aldimines (1j–1k), which were diversified by 
nucleophilic addition with three different Grignard reagents (scheme 4). 
 
 
Scheme 4: the preparation of key intermediates 1l-1q 
 
Scaffolds D was synthesized by using ring-closing metathesis (RCM) with Grubbs’ 
second-generation catalyst. The key intermediates 1l–1n were converted to 5a-5c, 
fused with 5-membered rings and 1o–1q were converted to 6a-6c, fused with 6-
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membered rings. Scheme 5, table 4. 
 
Scheme 5: the preparation of key intermediates 1l-1q 
 
By using Diels–Alder reaction of the diene moiety in intermediates 1l–1n with N-
substituted maleimides, six pyrimidine-containing tetracycles 7a–7f was 
synthesized (Scaffolds E) as enantiomers in moderate yields. Scheme 5, table 4. 
 
Table 4: Exploration of Scaffold D&E 
Product SM n R4 R5 Yield
a
% 
5a 1l 1 Methyl - 50 
5b 1m 1 Phenyl - 48 
5c 1n 1 4-MeO-Ph - 48 
6a 1o 2 Methyl - 48 
6b 1p 2 Phenyl - 60 
6c 1q 2 4-MeO-Ph - 52 
7a 1l 1 Methyl Phenyl 36 
7b 1m 1 Phenyl Phenyl 32 
7c 1n 1 4-MeO-Ph Phenyl 42 
7d 1l 1 Methyl 4-MeO-Ph 34 
7e 1m 1 Phenyl 4-MeO-Ph 36 
7f 1n 1 4-MeO-Ph 4-MeO-Ph 32 
a
Isolated yields 
In summary, we established five pathways to achieve different pyrimidine-
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embedded core skeletons from a key intermediate ortho-alkynylpyrimidine 
carbaldehydes with high molecular diversity and positions with potential 
functionalities for further modification. 
1.2.5. Chemoinformactics study 
In order to demonstrated the diverse orientation of our pDOS pathways, we 
performed the principal moment of inertia (PMI) analysis using PreADMET 2.0 
(BMDRC, Korea) and visualized with three principal components calculated using 
SAS 9.1 (SAS institute Inc., USA) to capture the shape-based distribution of small 
molecules as dots in an isosceles triangle defined by vertices (0,1), (0.5,0.5), and 
(1,1), which correspond to the rod, disc, and sphere shapes, respectively. 
 
Figure 6: (a) PMI plot depicting five core skeletons in their own color codes along with 
intermediate 1a and 1l in violet and black colors, respectively; (b) PCA of five different pyrimidine-
containing polyheterocycles. Compounds from each skeleton were differently color-coded. 
 
As shown in Figure 6c, five representative scaffolds and two key intermediates were 
dispersed in the PMI plot, indicating excellent diversity in the shape of each 
scaffold. Along with shape differences, we clearly visualized that the resulting five 
color-coded scaffolds were widely distributed in a 3D chemical space with 
maximum molecular diversity calculated by using unbiased molecular descriptors 
and analyzed by principal component analysis (PCA, Figure 6b). The molecular 
diversity of five different scaffolds was differentiated mainly by the topological 





A new privileged substructure-based Diversity-Oriented Synthesis (pDOS) strategy 
has been developed with pyrimidine as the privileged substructure
25
. The resulting 
five scaffolds consist of unique pyrimidine-embedded polyheterocycles fused with 
different ring sizes and orientations. This pDOS was achived by using very common 
practical reaction and condition such as silver- or iodine-mediated 6-endo 
cyclization followed by tandem cyclization with different reactants, RCM, Diels–
Alder reaction, which is very efficient for library construction. The molecular 
diversity of each scaffold was successfully confirmed by a series of computational 
studies, structural alignment of energy-minimized 3D conformers, shape diversity 
studies using PMI analysis, and in silico PCA analysis. We are currently using this 





II. Chapter 2 
Combinatorial Synthesis of Privileged Tetra-Substituted 
tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H,8H)-
dione library using Privileged Substructure-Based Diversity-
Oriented Synthesis (pDOS) 
 
2.1. Introduction 




) to be 
astronomic
26-27
. In addition, one of the great challenges in the field of chemical 
biology is the identification of novel small-molecule modulators that can 
specifically control the functions of gene products and elucidate the associated 
signaling pathways. Therefore, construction of small molecule libraries for High-
throughput Screening is one of object for synthetic chemist.  
The human body is a unity that including the complex of protein networks. Inside 
the body, each protein are linked by non-covalent interactions, they often activate or 
inhibit other members that lead to change the certain function. Stimulus signals 
from outside the cell are mediated of the signaling molecules to the inside of that 
cell by protein-protein interactions. Therefore, the development of novel small-
molecule modulators toward protein-protein interaction has been a key research 
field of interest. The β-turn is one of the three main secondary structural motifs 
found in proteins and peptides and occurs where the polypeptide strand reverses 
direction
28-31
. In addition, beta-turns play a crucial role in the interactions between 
peptides of proteins and receptors, enzymes, or antibodies
28-31
. In summary, it is an 
idea to develop library of bicyclic beta-turn mimetics small molecules with aim of 
discovering potent enzyme inhibitors and peptide hormone agonist and antagonists. 
The Tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H,8H)-dione are 
peptidomimetric structure with four sites of diversity readily accessible, based on its 
structure there are many expected biological activity, especially, the β-turn 
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mimetrics incorporating functionality at i to i+3 positions of such compounds are 
predictable (figure 7).  
 
  
Figure 7: a) β-turn style b) Structure of library compounds 
 
Eguchi et. al. has been working on solid-phase synthesis of bicyclic β-turn 
peptidomimetics (figure 8)
32-34
,  which is diversity at the 4 position of compound 
as shown in figure 6. In our study, one nitrogen atom was introduced in core 
structure (figure 7b) in order to increase the diversity of library compounds by using 
various substituted hydrazine.  
 
Figure 8: a) Beta-turn style b) structure of library compounds 
 
As illustrated in figure 9A, the β-turn consists of four amino acid residues 
designated from i to i+4 in which the distance between Ci to Ci+3 less than 7 
Angstrom. Our designed compounds has been calculated the β-turn mimetic 
structure by computation analysis in figure 9B, the results show that our compounds 










Figure 9: A) Mean and standard deviations of the CR distances taken from a set of 10 245 
β-turns in the PDB15. B) Distances between substituents in the energy-minimized conformer 
of targeted compound (using Accelrys discovery studio & Vconf interface) C) Overlap of 
designed compound and beta-turn structure  
  
As mentioned previously, β-turn is one of many expected biological activity for 
these compound that need to be studied in future, therefore, we construct the library 
compounds to provide a potential source for biological screening.  
Herein, we describe a practical synthetic pathway for enantiopure tetrahydro-1H-
pyrazino[2,1-c][1,2,4]triazine-4,7(6H,8H)-dione library via solid-phase parallel 




2.2. Results and discussion 
We initiated the library construction with four different substituents at the R1, R2, R3 
and R4 positions from a single key intermediate (figure 8). To achieve, we are first 
synthesized three different “2-(1-substitute-2-(substitute-carbamoyl)hydrazinyl) 
acetic acid” as acid coupling partner and nine amine solid-phase partners to afford 
82 library compounds.  
2.2.1. Preparation of acid coupling partners: 
 
Scheme 6: preparation of three acid intermediates 
As shown in scheme 6, the amine intermediate 2’a-c could be prepared through 
different hydrazine and isocyanate. In this work, we choose p-Tolylhydrazine as a 
fixing part (R1) and changing isocyanate to effort three types of acid coupling 
partners. The expanding library with diversity at R1 position will be reported in due 
course.  
When R1 is p-Tolyl, due to effect of phenyl group, the compound 2’a-c could be 
synthesized from 1 without protection of secondary amine. Then, the intermediate 
3’a-c was obtained from the SN2 reaction of 2’a-c with Bromo tert-butyl 
ethylacetate in basic condition. However, the diazo byproduct always formed at 70 % 
yield in basic condition via scheme 7.  
 
Scheme 7: by-product formation potential in base 
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Fortunately, among the many conditions tested when using potassium bicarbonate 
as base in DMF at 80
o
C, 3’a-c was obtained successfully with 65-70% yield. Finally, 
the intermediate 3’a-c was treated with 4N HCl in 1,4-dioxane for 48h to afford the 
acid coupling partner 4’a-c with 70-80 % yield. 
2.2.2. Synthesis of tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H,8H)-
dione via solid phase. 
Next, we optimized these synthetic routes in solid phase parallel synthesis format 
using commercially available bromoacetal resin (loading level 1.8mmol/g). For 
each final compound 100 mg of resins was used, scheme 8. 
 
Scheme 8: Synthesis of tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H,8H)-dione via 
solid phase. 
First, resin was treated with a number of primary amines (R3 group) gave the 
corresponding secondary amine 6’ by the displacement of the bromide. Then, it was 
coupled with nine Fmoc-α-amino acids (R4 group) using HATU, DIPEA in DMF. 
Fmoc-protection group was removed by treated 6’ with 20% piperidine in DMF, 
followed by coupling with acid coupling partner (which prepared above) afforded 9. 
Finally, product 10 was obtained by cleavage from the resin followed by 
stereoselective tandem cyclization was achieved by treatment with formic acid at 
room temperature. The products 10 were observed as the major product by LC-MS 
and NMR analyses of the crude products. Two representative compounds 10{a,2,9} 
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C NMR spectroscopy along 
with LC/MS analysis, as shown in table 5. 
Table 5: Purity and mass of representative Compounds 
 











 Calcd found 
10{a,2,9} 
   
75 92 574.25 574.22 
10{b,3,4}    
80 96 490.27 490.09 
a
Purities (%) were obtained by PDA-based LC/MS analysis of final compounds after cleavage from solid-support.
 
b
Purities (%) were obtained by PDA-based LC/MS analysis of final compounds after very fast purification  
The purities of all library members were measured using LC/MS equipped with a 
PDA detector after fast purified by using fast filter via silicagel in syringes, and 
their average purity was found to be 84%, as shown in table 6. 




The regioselectivity of product as cyclization via N-acyliminium intermediate was 
studied by various research group, which is only one direction of cyclization by the 
attaching of Nitrogen atom from the opposite side of the R4 group
31-36
 (figure 10).  
 
Figure 10: Expected mechanism31-36
 
The N-acyliminium ion formation has been reported in model compounds that 
allowed only one direction of cyclization
35-36
. We did the computational analysis of 
N-acyliminium transition state in process of tandem cyclization (using Accelrys 
discovery studio & Vconf interface), it confimed that the flavord structure lead to 
attack of Nitrogen atom from the up face compared with R4 group. Figure 10 and 11. 
 
Figure 11: Computational analysis of N-acyliminium transition state  
To confirm the structure, we did the crude-LCMS, crude-
1
H NMR, NOESY, 
COESY and chiral HPLC for the representative compounds, the resulting shown the 
bicyclic mimetics as the major product in all cases and only single peak in chiral 
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HPLC, (see supporting information). 2D-NMR experiments confirm the formation 
of only a single diastereomer. NOESY of 10{a,2,9} and 10{b,3,4} indicate the 
compound structure (10{b,3,4} was shown in figure 12) interaction (observed the 
key NOESY): H5(a) -H31(b), H5(a)-H10(c), in which the hydrogen at the ring 
junction (H5 or a) is trans to the hydrogen at the 7 (d) position. 
 
Figure 12: NOESY of 10{b,3,4} 
 
In summary, the 81 compounds of tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-
4,7(6H,8H)-dione library (R1 as p-Tolyl by using p-Tolylhydrazine) was 
synthesized with the diversity of these core skeletons was expanded through the 
introduction of various substituents at the R2 (by isocyanate), R3 (by using amine) 
and R4 (by using amino acid) positions from a single key intermediate with an 





We successfully constructed a practical and regioselective synthetic pathway for 
Privileged enantiopure tetrahydro-1H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H,8H)-
dione library via solid-phase parallel strategy. The regioselectivie was achived 
through the tandem cyclization of N-acyliminium in final step that allowed only one 
direction of cyclization, which is confirmed by our data including crude-LCMS, 
crude-NMR, chiral HPLC and computational analysis. The diversity of library was 
expanded through the introduction of various substituents at the R2 (by using 
isocyanate), R3 (by using amine) and R4 (by using amino acid) positions from a 
single key intermediate. This library is currently under biological evaluations 





III. EXPERIMENTAL SECTION 
3.1. Experimental section for chapter 1 
3.1.1. General synthetic procedure for compounds 1a–1c 
To the anhydrous DMF solution (60 mL) of 4-chloro-6-
(methylamino)pyrimidine-5-carbaldehyde (1.0 g), Pd(PPh3)2Cl2 (5 mol%), 
and CuI (20 mol%), terminal alkynes (2.0 equiv.) and triethylamine (1.6 mL, 
2.0 equiv.) were added under argon atmosphere. After being stirred at room 
temperature for 4 h, the reaction mixture was quenched with deionized water 
(200 mL). The resultant was extracted with EtOAc (100 mL  3) and 
combined organic layer was washed with brine (100 mL). After drying with 
anhydrous Na2SO4(s), the solvent was removed under the reduced pressure. 
The residue was purified by silica-gel flash column chromatography to 
obtain 1a–1c. 
Compound 1a: Yield: 79.5%; 
1
H NMR (400 MHz, CDCl3) δ 
10.55 (s, 1H), 8.91 (brs, 1H), 8.67 (s, 1H), 7.65–7.62 (m, 2H), 
7.47–7.38 (m, 3H), 3.14 (d, J = 5.2 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 192.5, 161.5, 160.4, 155.0, 132.4, 130.3, 128.6, 120.6, 
98.3, 83.8, 27.4; LRMS (ESI) m/z calcd for C14H11N3O [M+H]
+
: 
238.09; Found: 237.99. 
Compound 1b: Yield: 80.2%; 
1
H NMR (400 MHz, CDCl3) δ 
10.42 (s, 1H), 8.86 (s 1H), 8.60 (s, 1H), 3.11 (d, J = 5.2 Hz, 3H), 
2.50 (t, J = 6.8 Hz, 2H), 1.72–1.66 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 192.9, 161.4, 160.4, 155.5, 111.9, 
101.3, 76.0, 27.3, 21.5, 21.4, 13.6; LRMS (ESI) m/z calcd for C11H13N3O 
[M+H]
+
: 204.11; Found: 204.02. 
Compound 1c: Yield: 30.0%; 
1
H NMR (400 MHz, CDCl3) δ 10.42 (s, 1H), 
8.88 (brs, 1H), 8.63 (s, 1H), 5.64–5.63 (m, 1H), 5.54–5.53 (m, 1H), 3.13 (d, 
J = 4.8 Hz, 3H), 2.03 (t, J = 5.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
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192.6, 161.4, 160.4, 154.9, 126.6, 125.2, 111.8, 99.2, 82.6, 27.4, 





3.1.2. General synthetic procedure for compounds 1d–1i 
To a dichloroethane (DCE) solution of 1a–1c (3.0 mmol), amine (5.0 
equiv.) or tosylhydrazine (5.0 equiv.), Na2SO4, and AcOH were added. After 
stirring at 80 
o
C until starting materials were consumed, the reaction mixture 
was quenched with deionized water. The resultant was extracted with 
dichloromethane (DCM) twice and dried with anhydrous Na2SO4(s). After 
the solvent was removed under the reduced pressure, the residue was purified 
by silica-gel flash column chromatography to obtain 1d–1i. 
Compound 1d: Yield: 84%; 
1
H NMR (400 MHz, CDCl3) 
δ 10.12 (s, 1H), 9.18 (s, 1H), 8.58 (s, 1H), 7.60 (d, J = 6.8 
Hz, 2H), 7.40 (t, J = 7.6 Hz, 3H), 7.26 (d, J = 8.0 Hz, 2H), 
6.97 (d, J = 8.4 Hz, 2H), 3.85 (s, 3H), 3.18 (d, J = 4.8 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 160.2, 158.78, 158.61, 
156.3, 150.5, 143.5, 132.1, 129.8, 128.5, 122.3, 121.3, 114.6, 112.1, 97.0, 




Compound 1e: Yield: 68%; 
1
H NMR (400 MHz, CDCl3) δ 
10.06 (d, J = 4.4 Hz, 1H), 9.08 (s, 1H), 8.52 (s, 1H), 7.21 (d, 
J = 7.2 Hz, 2H), 6.95 (d, J = 6.8 Hz, 2H), 3.85 (s, 3H), 3.15 
(d, J = 4.8 Hz, 3H), 2.49 (t, J = 6.8 Hz, 3H), 1.73–1.64 (m, 
2H), 1.07 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 160.2, 158.6, 
158.5, 156.8, 151.2, 143.6, 122.3, 114.5, 111.9, 99.6, 76.8, 55.5, 27.4, 21.6, 
21.5, 13.6; LRMS (ESI) m/z calcd for C18H20N4O [M+H]
+




Compound 1f: Yield: 84.6%; 
1
H NMR (500 MHz, CDCl3) δ 
9.98 (brs, 1H), 8.97 (s, 1H), 8.55 (s, 1H), 7.62–7.60 (m, 2H), 
7.42–7.36 (m, 3H), 3.84 (t, J = 5.2 Hz, 2H), 3.71 (t, J = 5.2 Hz, 
2H), 3.4 (s, 3H), 3.11 (d, J = 4.8 Hz, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 161.8, 160.5, 158.4, 150.4, 111.3, 99.0, 77.1, 72.2, 61.0, 58.9, 27.2, 




Compound 1g: Yield: 92.3%; 
1
H NMR (500 MHz, CDCl3) δ 
9.91 (brs, 1H), 8.86 (s, 1H), 8.48 (s, 1H), 3.80 (t, J = 5.0 Hz, 
2H), 3.69 (t, J = 5.0 Hz, 2H), 3.39 (s, 3H), 3.08 (d, J = 4.5 Hz, 
3H), 2.47 (t, J = 7.0 Hz, 2H), 1.71–1.66 (m, 2H), 1.07 (t, J = 
7.5 Hz, 3H); 
13
C NMR (125 MHZ, CDCl3) δ 161.8, 160.5, 158.4, 150.4, 
111.3, 99.0, 77.1, 72.2, 61.0, 58.9, 27.2, 21.6, 21.5, 13.6; LRMS (ESI) m/z 
calcd for C14H20N4O [M+H]
+
: 261.16; Found: 261.05. 
Compound 1h: Yield: 60.3%; 
1
H NMR (400 MHz, CDCl3) δ 
8.45 (s, 1H), 8.38 (s, 2H), 7.83 (d, J = 6.8 Hz, 2H), 7.30 (d, J = 
7.6 Hz, 2H), 7.20 (t, J = 6.8 Hz, 1H), 7.12–7.06 (m, 4H), 3.04 
(d, J = 5.2 Hz, 3H), 2.38 (s, 3H); 
13
C NMR (100 MHz, CDCl3) 
δ 158.8, 157.5, 147.9, 145.5, 144.6, 135.1, 131.7, 129.8, 129.7, 128.1, 127.8, 
120.5, 110.2, 97.7, 84.2, 27.7, 21.6; LRMS (ESI) m/z calcd for C21H19N5O2S 
[M+H]
+
: 406.13; Found: 405.93. 
Compound 1i: Yield: 37.5%; 
1
H NMR (400 MHz, CDCl3) δ 
9.67 (s, 1H), 8.46–8.43 (s, 2H), 8.42 (s, 1H), 7.81 (d, J = 6.8 Hz, 
2H), 7.33 (d, J = 7.8 Hz, 2H), 7.38 (t, J = 7.6 Hz, 1H), 3.08 (d, J 
= 5.2 Hz, 3H), 2.43 (s, 3H), 2.18 (t, J = 7.2 Hz, 2H), 1.46–
1.37(m, 2H), 0.84 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.0, 
157.7, 149.0, 145.9, 144.7, 135.0, 129.8, 127.7, 109.9, 100.2, 76.4, 27.7, 
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21.6, 21.4, 21.3, 13.5; LRMS (ESI) m/z calcd for C18H21N5O2S [M+H]
+
: 
372.14; Found: 371.93. 
3.1.3. General synthetic procedure for compounds 1j–1o 
To a DCE solution of 5-((allylimino)methyl)-N-methyl-6-(3-methylbut-3-
en-1-yn-1-yl)pyrimidin-4-amine (2.0 mmol) or 5-((but-3-en-1-
ylimino)methyl)-N-methyl-6-(3–methylbut-3-en-1-yn-1-yl)pyrimidin-4-
amine (2.0 mmol), AgOTf (10 mol%) was added. After stirring at 80 
o
C for 2 
h, the reaction mixture was filtered under Na2SO4 pad and washed with DCM. 
After the removal of solvent under the reduced pressure, anhydrous THF was 
added under argon atmosphere. Then, Grignard reagent was added and 
stirred at room temperature for 2 h. The reaction mixture was quenched with 
aqueous NH4Cl solution and extracted twice with DCM. After drying with 
anhydrous Na2SO4(s), the solvent was removed under the reduced pressure. 
The residue was purified by silica-gel flash column chromatography to 
obtain 1j–1o. 
Compound 1j: Yield: 36%; 
1
H NMR (400 MHz, CDCl3) δ 
8.37 (s, 1H), 5.72–5.65 (m, 1H), 5.64 (s, 1H), 5.30 (t, J = 2.0 
Hz, 1H), 5.16 (t, J = 3.2 Hz, 1H), 5.12–5.10 (m, 1H), 5.08 (dd, 
J = 1.6 Hz, J = 1.2 Hz, 1H), 5.05 (dd, J = 1.2 Hz, J = 0.8 Hz, 
1H), 4.53 (d, J = 4.8 Hz, 1H), 3.71–3.65 (m, 1H), 3.59–3.53 (m, 1H), 2.99 (d, 
J = 4.4 Hz, 3H), 1.90 (s, 3H), 1.11 (d, J = 6.8 Hz, 3H) ; 
13
C NMR (100 MHz, 
CDCl3) δ 157.7, 156.8, 154.8, 153.6, 140.8, 135.2, 117.8, 117.1, 104.6, 102.1, 
54.1, 49.1, 28.1, 21.2, 17.1; LRMS (ESI) m/z calcd for C15H20N4 [M+H]
+
: 
257.11; Found: 257.07. 
Compound 1k: Yield: 42%; 
1
H NMR (300 MHz, CDCl3) δ 
8.48 (s, 1H), 7.31 (m, 5H), 5.86–5.73 (m, 1H), 5.31 (s, 1H), 
5.25–5.21 (m, 2H), 5.13 (s, 1H), 4.21 (d, J = 3.9 Hz, 1H), 3.83 
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(dd, J = 5.1 Hz, J = 5.1 Hz, 1H), 3.60 (dd, J = 6.6 Hz, J = 6.6 Hz, 1H), 2.94 
(d, J = 4.8 Hz, 3H), 1.84 (s, 3H);
 13
C NMR (100 MHz, CDCl3) δ 157.4, 
156.9, 153.9, 152.7, 134.4, 128.8, 128.4, 126.7, 118.9, 118.2, 117.9, 66.6, 
61.6, 56.9, 53.5, 47.1, 28.2, 21.1; LRMS (ESI) m/z calcd for C20H22N4 
[M+H]
+
: 319.18; Found: 319.12. 
Compound 1l: Yield: 38%; 
1
H NMR (400 MHz, CDCl3) δ 
8.43 (s, 1H), 7.21 (d, J = 4.8 Hz, 2H), 6.79 (d, J = 3.2 Hz, 
2H), 5.81–5.71 (m, 1H), 5.56 (s, 1H), 5.27 (d, J = 6.4 Hz, 
1H), 5.23–5.15 (m, 2H), 5.09 (d, J = 2.0 Hz, 1H), 4.19 (d, J 
= 4.4 Hz, 1H), 3.83–3.77 (m, 1H), 3.75 (s, 3H), 3.59–3.46 (m, 1H), 2.90 (d, J 
= 4.8 Hz, 3H), 1.81 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.5, 158.4, 
157.3, 155.5, 154.5, 140.7, 134.6, 132.9, 128.0, 118.0, 117.7, 114.0, 101.1, 
85.5, 77.3, 56.3, 55.2, 53.3, 28.2, 21.2; LRMS (ESI) m/z calcd for 
C21H24N4O [M+H]
+
: 349.20; Found: 349.01. 
Compound 1m: Yield: 46%; 
1
H NMR (500 MHz, CDCl3) δ 
8.40 (s, 1H), 5.70–5.62 (m, 1H), 5.61 (s, 1H), 5.32 (s, 1H), 
5.17 (s, 1H), 4.98 (t, J = 4.5 Hz, 1H), 4.94 (s, 1H), 4.54 (d, J = 
4.0 Hz, 1H), 4.28 (dd, J = 6.5 Hz, J = 7.0 Hz, 1H), 4.13 (dd, J 
= 7.0 Hz, J = 6.5 Hz, 1H), 3.34–3.29 (m, 1H), 3.11 (d, J = 5.0 Hz, 1H), 3.07 
(d, J = 3.6, 3H), 2.23–2.18 (m, 2H), 2.05 (s, 1H), 1.95 (s, 3H), 1.27 (t, J = 
14.5 Hz, 1H), 1.18 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 157.5, 
156.4, 154.0, 141.1, 134.8, 118.0, 116.9, 104.2, 101.1, 51.6, 50.4, 34.5, 28.1, 




Compound 1n: Yield: 50%; 
1
H NMR (400 MHz, CDCl3) δ 
8.44 (s, 1H), 7.28–7.24 (m, 5H), 5.73–5.63 (m, 1H), 5.57 (s, 
1H), 5.28 (dd, J = 0.8 Hz, J = 0.8 Hz, 1H), 5.24 (s, 1H), 5.11–
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5.10 (m, 1H), 4.99 (dd, J = 1.6 Hz, J = 1.6 Hz, 1H), 4.98–4.97 (m, 1H), 4.95 
(t, J = 4.8 Hz, 1H), 4.40 (d, J = 4.4 Hz, 1H), 3.41–3.33 (m, 1H), 3.15–3.08 
(m, 1H), 2.95 (d, J = 4.8 Hz, 3H), 2.31–2.25 (m, 2H), 1.81 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3) δ 158.5, 156.9, 155.3, 154.8, 140.9, 140.8, 134.7, 128.8, 
128.4, 126.5, 118.1, 117.1, 103.0, 101.3, 58.2, 51.5, 50.8, 33.7, 29.2, 21.1; 
LRMS (ESI) m/z calcd for C21H24N4 [M+H]
+
: 333.20; Found: 333.04. 
Compound 1o: Yield: 34%;
 1
H NMR (400 MHz, CDCl3) δ 
8.44 (s, 1H), 7.18 (d, J = 3.2 Hz, 2H), 6.79 (d, J = 2.8 Hz, 
2H), 5.71–5.63 (m, 1H), 5.55 (s, 1H), 5.26 (s, 1H), 5.16 (s, 
1H), 5.09 (s, 1H), 4.99–4.98 (m, 2H), 4.95 (s, 1H), 4.21 (d, J 
= 4.8 Hz, 1H), 3.80 (t, J = 16.4 Hz, 1H), 3.76 (s, 3H), 3.37–3.30 (m, 1H), 
3.13–3.05 (m, 1H), 2.94 (d, J = 4.8 Hz, 3H), 2.27 (dd, J = 7.6 Hz, J = 6.0 Hz, 
2H), 1.80 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.5, 158.3, 157.3, 155.6, 
154.5, 140.9, 134.8, 133.1, 128.7, 127.8, 117.9, 117.0, 114.1, 113.7, 103.3, 
101.5, 57.6, 55.2, 51.3, 33.6, 28.2, 21.2; LRMS (ESI) m/z calcd for 
C22H26N4O [M+H]
+
: 363.21; Found: 362.98. 
3.1.4. General procedure for the preparation of scaffold A (2a–2f) 
To a DCE solution of 1d–1g (0.3 mmol), AgOTf (10 mol%) and AcOH 
(2.0 equiv.) were added. After stirring at 80 
o
C for 2 h, the reaction mixture 
was filtered under Na2SO4 pad and washed with DCM. After the removal of 
solvent under the reduced pressure, the reaction mixture was dissolved with 
dimethylformamide (DMF). 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 
dialkylmalonates were added to the solution and stirred at 80 
o
C for 2 h. The 
resultant was quenched with deionized water and extracted twice with ethyl 
acetate (EtOAc). Combined organic layer was washed with brine and dried 
with anhydrous Na2SO4(s). After the solvent was removed under the reduced 
pressure, the residue was purified by silica-gel flash column chromatography 
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to obtain 2a–2f. 
Compound 2a: Yield: 74%; 
1
H NMR (400 MHz, CDCl3) 
δ 12.57 (s, 1H), 8.78 (s, 1H), 8.68 7.42–7.34 (m, 5H), 6.76 
(d, J = 6.8 Hz, 2H), 6.69 (d, J = 6.4 Hz, 2H), 5.85 (s, 1H), 
5.43 (q, J = 7.2 Hz, 2H), 3.80 (s, 3H), 3.73 (s, 3H), 1.40 (t, 
J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 165.1, 
162.6, 159.8, 157.6, 156.4, 155.2 ,137.9, 136.7, 132.8, 129.5, 128.54, 128.51, 
124.7, 121.1, 114.0, 105.4, 92.2, 61.7, 55.4, 28.6, 14.3; HRMS (FAB+) m/z 
calcd for C26H24N4O4 [M+H]
+
: 457.1876; Found: 457.1877. 
Compound 2b: Yield: 70%; 
1
H NMR (500 MHz, CDCl3) δ 
12.58 (s, 1H), 8.79 (s, 1H), 8.73 (s, 1H), 7.42–7.36 (m, 5H), 
6.77 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.0 Hz, 2H), 5.86 (s, 
1H), 3.96 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 165.4, 162.6, 159.7, 158.9, 157.7, 156.4, 
155.2, 138.4, 136.6, 132.8, 129.5, 128.52, 128.49, 124.7, 120.4, 114.0, 105.3, 
92.1, 55.3, 52.6, 28.7; HRMS (FAB+) m/z calcd for C25H22N4O4 
[M+H]
+
:443.1719; Found: 443.1728. 
Compound 2c: Yield: 97%; 
1
H NMR (500 MHz, CDCl3) 
δ 11.10 (s, 1H), 8.71 (s, 1H), 8.62 (s, 1H), 7.49–7.47 (m, 
3H), 7.44–7.42 (m, 2H), 5.55 (s, 1H), 3.91 (s, 3H), 3.77 (s, 
3H), 3.49 (t, J = 5.5 Hz, 2H), 3.42 (t, J = 6.0 Hz, 2H), 3.40 
(s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 165.5, 163.6, 
162.8, 159.9, 157.8, 155.1, 138.6, 136.4, 129.5, 128.6, 127.8, 119.6, 104.5, 
89.3, 71.9, 59.0, 52.5, 44.9, 28.6; HRMS (FAB+) m/z calcd for C21H22N4O4 
[M+H]
+





Compound 2d: Yield: 84%; 
1
H NMR (500 MHz, CDCl3) 
δ 12.50 (s, 1H), 8.69 (s, 1H), 8.63 (s, 1H), 7.13 (d, J = 8.0 
Hz, 2H), 6.93 (d, J = 8.5 Hz, 2H), 5.66 (s, 1H), 4.44 (q, J 
= 7.0 Hz, 2H), 3.85 (s, 3H), 3.77 (s, 3H), 2.40 (t, J = 7.5 
Hz, 2H), 1.58–1.54 (m, 2H), 1.43 (t, J = 7.0 Hz, 3H), 
0.90 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 165.4, 164.1, 162.7, 
159.9, 157.5, 155.1, 138.4, 127.8, 127.7, 120.2, 115.0, 113.7, 104.2, 87.3, 
61.6, 55.9, 28.9, 22.1, 14.4, 14.2; HRMS (FAB+) m/z calcd for C23H26N4O4 
[M+H]
+
: 423.2032; Found: 423.2031. 
Compound 2e: Yield: 83%; 
1
H NMR (500 MHz, CDCl3) 
δ 12.51 (s, 1H), 8.73 (s, 1H), 8.63 (s, 1H), 7.13 (d, J = 
8.5 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 5.66 (s, 1H), 3.98 
(s, 3H), 3.85 (s, 3H), 3.77 (s, 3H), 2.40 (t, J = 7.5 Hz, 
2H), 1.59–1.54 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H); 
13
C 
NMR (125 MHZ, CDCl3) δ 165.8, 164.2, 162.7, 159.8, 157.7, 157.5, 155.1, 
138.8, 138.6, 131.3, 127.3, 119.5, 114.4, 104.2, 87.6, 55.5, 52.6, 35.4, 28.6, 




Compound 2f: Yield: 77%; 
1
H NMR (500 MHz, CDCl3) 
δ 11.17 (s, 1H), 8.67 (s, 1H), 8.57 (s, 1H), 5.48 (s, 1H), 
3.96 (s, 3H), 3.75 (s, 3H), 3.62 (t, J = 5.0 Hz, 2H), 3.57 (t, 
J = 5.0 Hz, 2H), 3.45 (s, 3H), 2.40 (t, J = 8.0 Hz, 2H), 
1.71–1.61 (m, 2H), 1.06 (t, J = 7.0 Hz, 3H); 
13
C NMR 
(100 MHZ, CDCl3) δ 165.9, 165.4, 162.7, 160.0, 157.8, 155.1, 138.9, 118.9, 
103.8, 86.8, 71.6, 59.1, 52.5, 43.2, 35.8, 29.6, 28.5, 22.0, 14.0; HRMS 
(FAB+) m/z calcd for C18H24N4O4 [M+H]
+
: 361.1876; Found: 361.1873. 
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3.1.5. General procedure for the preparation of scaffold B (3a–3i) 
To the t–BuOH solution of 1a–1b (0.4 mmol), diaminoalkane (5.0 equiv.) 
was added. After stirring at 80 
o
C for 2 h, iodine (10.0 equiv.) was added to 
the reaction mixture and stirred at 80 
o
C for additional 1 h. The reaction 
mixture was quenched with aqueous sodium thiosulfate solution and 
extracted twice with DCM. After drying with anhydrous Na2SO4(s), the 
solvent was removed under the reduced pressure. The residue was purified 
by silica-gel flash column chromatography to obtain 3a–3i. 
Compound 3a: Yield: 60%; 
1
H NMR (400 MHz, CDCl3) δ 
9.52 (d, J = 4.0 Hz, 1H), 8.63 (s, 1H), 7.51 (t, J = 7.2 Hz, 3H), 
7.30 (d, J = 7.2 Hz, 2H), 3.97 (t, J = 10.0 Hz, 2H), 3.66 (t, J = 
10.0 Hz, 2H), 3.13 (d, J = 5.2 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 160.6, 160.4, 157.2, 155.8, 150.8, 138.0, 129.7, 129.0, 
127.9, 99.3, 73.2, 52.8, 50.1, 27.6; HRMS (FAB+) m/z calcd for C16H14IN5 
[M+H]
+
:404.0372; Found: 404.0370. 
Compound 3b: Yield: 35%; 
1
H NMR (400 MHz, CDCl3) δ 
9.48 (brs, 1H), 8.52 (s, 1H), 4.08 (t, J = 5.2 Hz, 4H), 3.09 (d, J 
= 5.2 Hz, 3H), 2.78 (t, J = 8.0 Hz, 2H), 1.72–1.62 (m, 2H), 1.10 
(t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 160.5, 160.2, 
157.0, 156.1, 151.1, 98.5, 72.9, 52.7, 48.3, 40.3, 29.7, 27.5, 




Compound 3c: Yield: 57%; 
1
H NMR (400 MHz, CDCl3) δ 
8.57 (s, 1H), 7.53–7.48 (m, 3H), 7.25–7.23 (m, 2H), 3.58 (t, J = 
5.6 Hz, 2H), 3.46 (t, J = 5.6 Hz, 2H), 3.12 (s, 3H), 1.79 (quintet, 
J = 5.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 161.1, 159.0, 
155.0, 151.8, 149.4, 138.9, 129.4, 129.2, 128.5, 103.7, 77.7, 
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49.6, 43.6, 27.6, 20.9; HRMS (FAB+) m/z calcd for C16H14IN5 
[M+H]
+
:418.0529; Found: 418.0526. 
Compound 3d: Yield: 53%; 
1
H NMR (400 MHz, CDCl3) δ 
11.52 (brs, 1H), 8.51 (s, 1H), 3.92 (t, J = 6.0 Hz, 2H), 3.60 (t, J 
= 6.0 Hz, 2H), 3.06 (s, 3H), 2.95 (t, J = 8.0 Hz, 2H), 
1.95(quintet, J = 6.0 Hz, 2H), 1.68–1.58 (m, 2H), 1.09 (t, J = 
8.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 160.9, 158.6, 
154.8, 151.2, 149.6, 103.1, 78.3, 46.7, 43.4, 39.3, 27.5, 21.1, 21.0, 14.0; 
HRMS (FAB+) m/z calcd for C14H18IN5 [M+H]
+
: 384.0685; Found: 
384.0688. 
Compound 3e: Yield: 25%; 
1
H NMR (400 MHz, CDCl3) δ 
8.59 (s, 1H), 7.51–7.49 (m, 3H), 7.36–7.39 (m, 2H), 3.91–
3.89 (m, 2H), 3.60–3.57 (m, 2H), 3.11 (s, 3H), 1.98–1.92 (m, 
2H), 1.67–1.60 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 
160.6, 158.7, 155.2, 153.0, 138.1, 129.6, 129.4, 128.6, 104.7, 
78.2, 53.3, 48.6, 28.0, 27.7, 26.2, 25.2; HRMS (FAB+) m/z calcd for 
C18H18IN5 [M+H]
+
: 432.0685; Found: 432.0679. 
Compound 3f: Yield: 39%; 
1
H NMR (400 MHz, CDCl3) δ 
11.08 (brs, 1H), 8.53 (s, 1H), 3.91 (t, J = 5.6 Hz, 4H), 3.06 (s, 
3H), 2.81 (t, J = 8.0 Hz, 2H), 1.98 (t, J = 3.2 Hz, 4H), 1.75–
1.69 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 160.4, 158.5, 154.9, 152.9, 152.5, 104.0, 78.3, 50.8, 
48.3, 38.7, 29.7, 27.5, 26.2, 25.1, 22.2, 14.1; HRMS (FAB+) m/z calcd for 
C15H20IN5 [M+H]
+
: 398.0842; Found: 398.0844. 
Compound 3g: Yield: 47%; 
1
H NMR (500 MHz, CDCl3) δ 
9.78 (d, J = 4.5 Hz, 1H), 8.83 (s, 1H), 7.59–7.53 (m, 3H), 7.37 
(d, J = 7.5 Hz, 2H), 3.33 (d, J = 5.0 Hz, 3H), 2.81 (t, J = 6.5 Hz, 
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2H), 1.80–1.73 (m, 4H), 1.60–1.58 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 
159.2, 157.3, 148.0, 143.9, 140.3, 137.6, 130.20, 130.05, 128.3, 122.2, 101.0, 
90.4, 28.0, 25.2, 23.5, 23.3, 22.4; HRMS (FAB+) m/z calcd for C20H20IN5 
[M+H]
+
: 458.0685; Found: 458.0678. 
Compound 3h: Yield: 10%; 
1
H NMR (400 MHz, CDCl3) δ 
9.50 (brs, 1H), 8.87 (s, 1H), 7.63 (t, J = 6.4 Hz, 3H), 7.49 (d, J 
= 1.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 2H), 7.08 (d, J = 1.2 Hz, 1H), 
3.33 (d, J = 4.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.3, 
157.8, 149.3, 143.5, 141.3, 136.5, 131.2, 130.1, 129.5, 129.0, 
114.0, 101.2, 89.6, 28.0; HRMS (FAB+) m/z calcd for C16H12IN5 [M+H]
+
: 
402.0216; Found: 402.0212. 
Compound 3i: Yield: 34%; 
1
H NMR (400 MHz, CDCl3) δ 
9.48 (brs, 1H), 8.83 (s, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.63 (d, J 
= 1.6 Hz, 1H), 3.39 (t, J = 8.0 Hz, 2H), 3.30 (d, J= 5.2 Hz, 3H), 
1.88–1.79 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 159.3, 157.7, 149.0, 143.9, 141.3, 131.7, 112.1, 
100.6, 89.3, 39.6, 28.0, 19.6, 14.1; HRMS (FAB+) m/z calcd for C13H14IN5 
[M+H]
+
: 368.0372; Found: 368.0375. 
3.1.6. General procedure for the preparation of scaffold C (4a–4f) 
To the DCE of 1h–1i (0.25 mmol), AgOTf (20 mol%) was added. After 
stirring at 80 
o
C for 2 h, the reaction mixture was cooled to room temperature. 
After the addition of DBU (3.0 equiv.) and terminal alkyne (1.5 equiv.), the 
reaction mixture was stirred for 2 h. The resultant was quenched with water 
and extracted with DCM in two times. After drying with anhydrous 
Na2SO4(s), the solvent was removed under the reduced pressure. The residue 
was purified by silica-gel flash column chromatography to obtain 4a–4f. 
Compound 4a: Yield: 64%; 
1
H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 
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8.00–7.97 (m, 2H), 7.92 (d, J = 8.0, 2H), 7.55–7.53 (m, 
3H), 7.41 (t, J = 7.2 Hz, 2H), 7.35 (t, J = 7.6 Hz, 1H), 7.13 
(s, 1H), 7.07 (s, 1H), 5.77 (d, J = 5.6 Hz, 1H), 3.29 (d, J= 
4.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 158.3, 156.8, 
153.6, 150.3, 144.8, 136.3, 132.7, 130.0, 129.7, 128.8, 128.7, 128.3, 126.4, 
112.6, 103.7, 95.8, 28.7; HRMS (FAB+) m/z calcd for C22H17N5 [M+H]
+
: 
352.1562; Found: 352.1556. 
 
Compound 4b: Yield: 72%; 
1
H NMR (400 MHz, CDCl3) 
δ 8.73 (s, 1H), 7.93–7.91 (m, 2H), 7.53–7.49 (m, 3H), 7.05 
(s, 1H), 6.47 (s, 1H), 5.69 (d, J = 4.8 Hz, 1H), 3.28 (d, J = 
4.8 Hz, 3H), 2.19–2.13 (m, 1H), 1.07–1.02 (m, 2H), 0.91–
0.87 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 158.7, 158.3, 
156.6, 150.2, 144.6, 135.7, 132.8, 129.9, 129.5, 128.2, 111.6, 103.4, 95.1, 




Compound 4c: Yield: 51%; 
1
H NMR (400 MHz, CDCl3) δ 
8.75 (s, 1H), 8.00–7.97 (m, 2H), 7.54–7.52 (m, 3H), 7.12 (s, 
1H), 6.92 (s, 1H), 5.77 (s, 1H), 5.74 (s, 1H), 5.26 (s, 1H),  
3.31 (d, J = 5.2 Hz, 3H), 2.22 (s, 3H); 
13
C NMR (100 MHZ, 
CDCl3) δ 158.3, 156.8, 154.9, 150.3, 144.8, 136.7, 135.8, 
132.6, 130.0, 129.7, 128.2, 114.7, 112.4, 103.6, 95.6, 28.7, 20.3; HRMS 
(FAB+) m/z calcd for C19H17N5 [M+H]
+
: 316.1562; Found: 316.1563. 
Compound 4d: Yield: 70%; 
1
H NMR (400 MHz, CDCl3) 
δ 8.73 (s, 1H), 8.00 (d, J = 7.6 Hz, 2H), 7.46 (t, J = 7.6 Hz, 
2H), 7.38 (t, J = 7.6 Hz, 1H), 6.98 (s, 1H), 6.88 (s, 1H), 
5.67 (d, J = 4.4 Hz, 1H), 3.27 (d, J = 4.8 Hz, 3H), 3.18 (t, J 
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= 7.8 Hz, 2H), 1.97–1.87 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 158.3, 156.6, 153.3, 150.1, 146.7, 135.4, 132.6, 128.73, 
128.71, 126.4, 109.9, 103.1, 95.6, 33.1, 28.6, 19.7, 13.9; HRMS (FAB+) m/z 
calcd for C19H19N5 [M+H]
+
: 318.1719; Found: 318.1717. 
Compound 4e: Yield: 69%; 
1
H NMR (400 MHz, CDCl3) 
δ 8.71 (s, 1H), 6.84 (s, 1H), 6.43 (s, 1H), 5.62 (d, J = 4.0 
Hz, 1H), 3.27 (d, J = 4.8 Hz, 3H), 3.15 (t, J = 7.6 Hz, 2H), 
2.22–2.15(m, 1H), 1.96–1.86 (m, 2H), 1.1–1.07 (m, 5H), 
0.96–0.92 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 158.4, 
158.2, 156.5, 146.5, 135.8, 108.9, 102.8, 95.1, 33.1, 28.6, 19.6, 13.9, 9.7, 9.0; 
HRMS (FAB+) m/z calcd for C16H19N5 [M+H]
+
: 282.1719; Found: 282.1718. 
Compound 4f: Yield: 69%; 
1
H NMR (400 MHz, CDCl3) δ 
8.72 (s, 1H), 6.87 (s, 1H), 6.84 (s, 1H), 5.80 (s, 1H), 5.67 
(d, J = 4.4 Hz, 1H), 5.29–5.28 (m, 1H), 3.28 (d, J = 4.8 Hz, 
3H), 3.17 (t, J = 7.6 Hz, 2H), 2.28 (s, 3H), 1.97–1.87 (m, 
2H), 1.08 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 
δ 158.3, 156.6, 154.6, 150.2, 146.8, 136.8, 134.9, 114.4, 109.8, 103.1, 95.4, 
33.1, 28.6, 20.3, 19.7, 13.9; HRMS (FAB+) m/z calcd for C16H19N5 [M+H]
+
: 
282.1719; Found: 282.1718. 
3.1.7. General procedure for the preparation of scaffold D (5a–5c, 6a–6c) 
To an anhydrous DCM solution of 1j–1o (0.1 mmol), second generation 
Grubb’s catalyst (10 mol%) was added under argon atmosphere. After 
stirring at 40 
o
C for 2 h, second generation Grubb’s catalyst (10 mol%) was 
added to the reaction mixture and stirred for additional 3 h. After the removal 
of solvent under the reduced pressure, the residue was purified by silica-gel 





Compound 5a: Yield: 50%;
 1
H NMR (400 MHz, CDCl3) δ 8.54 (s, 
1H), 6.63 (d, J = 2.8 Hz, 1H), 6.07 (d, J = 2.8 Hz, 1H), 5.06 (dd, J 
= 6.8 Hz, J = 7.6 Hz, 1H), 4.6 (s, 1H), 3.97 (d, J = 20.8 Hz, 1H), 
3.83 (d, J = 21.2 Hz, 1H), 3.10 (d, J = 4.8 Hz, 3H), 2.07 (s, 3H), 
1.52 (d, J = 6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 158.6, 157.9, 156.8, 
151.5, 116.3, 113.4, 110.4, 62.2, 48.6, 29.1, 28.3, 23.1, 10.7; HRMS (FAB+) 
m/z calcd for C13H16N4 [M+H]
+
: 229.1453; Found: 229.1458. 
Compound 5b: Yield: 48%; 
1
H NMR (400 MHz, CDCl3) δ 
8.59 (s, 1H), 7.56–7.21 (m, 5H), 6.58 (d, J = 2.8 Hz, 1H), 6.02 
(d, J = 2.8 Hz, 1H), 5.88 (s, 1H), 4.48 (s, 1H), 4.06 (s, 2H), 2.90 
(d, J = 4.8 Hz, 3H), 2.06 (s, 3H); 
13
C NMR (100 MHz, CDCl3) 
δ 159.2, 157.6, 157.1, 140.0, 129.7, 129.0, 126.9, 121.2, 116.9, 113.5, 110.97, 
110.91, 77.6, 76.7, 57.3, 29.2, 28.4, 10.7; HRMS (FAB+) m/z calcd for 
C18H18N4 [M+H]
+
: 291.1610; Found: 291.1606. 
Compound 5c: Yield: 48%;
 1
H NMR (500 MHz, CDCl3) δ 
8.60 (s, 1H), 7.17 (d, J = 9.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 
2H), 6.60 (d, J = 2.5 Hz, 1H), 6.02 (d, J = 3.0 Hz, 1H), 
5.86 (s, 1H), 4.47 (s, 1H), 4.06 (s, 2H), 3.77 (s, 3H), 2.93 
(d, J = 4.5 Hz, 3H), 2.07 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.9, 
159.2, 157.5, 142.5, 132.0, 129.1, 115.7, 113.4, 111.0, 107.7, 100.7, 61.8, 
51.0, 39.5, 37.2, 29.2, 26.2; HRMS (FAB+) m/z calcd for C19H20N4 [M+H]
+
: 
321.1715; Found: 321.1709. 
Compound 6a: Yield: 48%;
 1
H NMR (400 MHz, CDCl3) δ 8.36 (s, 
1H), 5.89 (s, 1H), 5.48 (s, 1H), 4.36 (dd, J = 11.6 Hz, J = 6.4 Hz 
1H), 4.30 (s, 1H), 3.34–3.27 (m, 1H), 3.08–3.06 (m, 1H), 3.03 (d, 
J = 3.6 Hz, 3H), 2.33 (d, J = 4.0 Hz, 2H), 1.91 (s, 1H), 1.19 (d, J = 
 
37 
6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 157.0, 152.7, 132.3, 130.1, 
127.3, 109.9, 94.4, 53.9, 45.1, 29.7, 28.1, 25.0, 18.7, 13.6; HRMS (FAB+) 
m/z calcd for C14H18N4 [M+H]
+
: 243.1610; Found: 243.1614. 
Compound 6b: Yield: 60%; 
1
H NMR (400 MHz, CDCl3) δ 
8.39 (s, 1H), 7.42–7.40 (m, 2H), 7.32–7.29 (m, 2H), 5.81 (s, 
1H), 5.47 (s, 1H), 5.16 (s, 1H), 4.01 (s, 1H), 2.87–2.85 (d, J 
= 4.8 Hz, 3H), 2.82–2.75 (m, 1H), 1.91 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3) δ 157.60, 157.56, 155.7, 147.6, 139.7, 129.8, 129.0, 
128.9, 127.2, 104.4, 94.3, 76.7, 63.4, 44.7, 35.6, 35.0, 28.2, 26.97, 26.85, 
26.32, 26.29, 26.12, 26.10, 24.7, 18.9; HRMS (FAB+) m/z calcd for 
C19H20N4 [M+H]
+
: 305.1766; Found: 305.1761. 
Compound 6c: Yield: 52%; 
1
H NMR (400 MHz, CDCl3) 
δ 8.38 (s, 1H), 7.32 (d. J = 2.4 Hz, 2H), 6.83 (d, J = 2.0 
Hz, 2H), 5.81 (s, 1H), 5.46 (s, 1H), 5.14 (s, 1H), 4.53 (s, 
1H), 3.96 (s, 3H), 2.86 (d, J = 4.8 Hz, 3H), 2.36 (s, 2H), 
2.30 (s, 2H), 1.90 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 158.6, 158.0, 
138.7, 128.5, 127.4, 123.7, 119.0, 114.2, 98.4, 95.7, 76.7, 60.1, 55.1, 48.3, 
37.5, 29.7, 28.2, 24.7, 22.9, 21.5; HRMS (FAB+) m/z calcd for C20H22N4O 
[M+H]
+
: 335.1872; Found: 335.1875. 
3.1.8. General procedure for the preparation of scaffold E (7a–7f) 
To a toluene solution of 1j–1l (0.1 mmol), maleimide (2.0 equiv.) was 
added. After stirring at 85 
o
C for 3 days, organic solvent was removed under 
the reduced pressure. The residue was purified by silica-gel flash column 
chromatography to obtain 7a–7f. 
Compound 7a: Yield: 36%; 
1
H NMR (400 MHz, 
CDCl3) δ 8.30 (s, 1H), 7.41–7.29 (m, 5H), 5.72–5.69 
(m, 1H), 5.36 (d, J = 6.8 Hz, 1H), 5.21–5.13 (m, 2H), 
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5.06 (s, 1H), 4.27–4.20 (m, 2H), 3.96–3.87 (m, 2H), 3.79–3.75 (m, 1H), 
3.70–3.63 (m, 1H), 2.99 (d, J = 4.4 Hz, 3H), 2.96–2.89 (m, 1H), 1.96 (s, 3H), 
1.18 (d, J = 6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 179.7, 179.5, 177.0, 
157.32, 157.27, 156.2, 156.1, 153.9, 152.3, 139.9, 134.7, 133.1, 129.0, 128.2, 
126.78, 126.76, 119.7, 117.4, 117.2, 104.3, 76.7, 53.5, 53.3, 48.9, 48.7, 41.3, 
40.3, 37.9, 35.8, 29.7, 28.2, 22.3, 16.4, 16.3; HRMS (FAB+) m/z calcd for 
C25H27N5O2 [M+H]
+
: 430.2243; Found: 430.2236. 
Compound 7b: Yield: 32%; 
1
H NMR (400 MHz, 
CDCl3) δ 8.35 (s, 1H), 7.75–7.26 (m, 10H), 5.77–5.71 
(m, 1H), 5.34 (s, 1H), 5.30–5.26 (m, 2H), 5.23 (s, 1H), 
4.09–4.08 (m, 2H), 4.02–3.95 (m, 2H), 3.61–3.55 (m, 
1H), 2.94 (m, 1H), 2.91 (d, J = 4.8 Hz, 3H), 2.30 (d, J = 4.8 Hz, 1H), 1.75 (s, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 179.6, 176.7, 158.2, 156.8, 156.7, 153.9, 
140.4, 133.9, 133.4, 129.3, 129.0, 128.9, 128.7, 128.2, 128.1, 127.2, 126.9, 
126.77, 126.70, 119.2, 118.2, 118.1, 103.4, 56.9, 52.9, 40.4, 37.4, 35.6, 29.7, 




Compound 7c: Yield: 42%; 
1
H NMR (400 MHz, 
CDCl3) δ 8.35 (s, 1H), 7.50–7.20 (m, 7H), 6.89–6.86 
(m, 2H), 5.78–5.74 (m, 1H), 5.35 (s, 1H), 5.33–5.26 
(m, 2H), 5.21 (s, 1H), 4.06–4.03 (m, 2H), 3.98–3.96 
(m, 2H), 3.81 (s, 3H), 3.63–3.57 (m, 1H), 3.01–2.96 (m, 1H), 2.95 (d, J = 
12.0 Hz, 3H), 2.85 (d, J = 4.8 Hz, 1H), 1.77 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 178.4, 177.3, 170.7, 159.7, 159.2, 158.2, 158.0, 156.6, 150.1, 133.9, 
132.6, 127.99, 127.86, 118.2, 114.5, 114.36, 114.32, 86.0, 76.7, 64.6, 55.5, 
55.3, 40.4, 35.5, 29.7, 28.3, 26.7, 25.0, 17.1; HRMS (FAB+) m/z calcd for 
C31H31N5O3 [M+H]
+
: 522.2505; Found: 522.2488. 
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Compound 7d: Yield: 34%; 
1
H NMR (400 MHz, 
CDCl3) δ 8.30 (s, 1H), 7.28–7.20 (m, 3H), 6.97–6.93 
(m, 1H), 5.74–5.63 (m, 1H), 5.36 (d, J = 7.6 Hz, 1H), 
5.22–5.13 (m, 2H), 5.05 (s, 1H), 4.27–4.17 (m, 2H), 
3.90–3.83 (m, 2H), 3.80 (s, 3H), 3.75–3.63 (m, 2H), 2.93 (d, J = 9.6 Hz, 3H), 
2.94–2.85 (m, 1H), 1.96 (s, 3H), 1.18 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 177.2, 159.3, 157.37, 157.33, 156.2, 156.1, 153.9, 152.3, 
139.9, 134.8, 127.94, 127.92, 119.7, 117.4, 117.2, 116.4, 114.40, 114.38, 
55.48, 55.46, 53.3, 48.9, 48.7, 41.3, 40.3, 37.8, 29.7, 28.20, 28.17, 22.3, 16.4, 
16.3; HRMS (FAB+) m/z calcd for C26H29N5O3 [M+H]
+
: 460.2349; Found: 
460.2359. 
Compound 7e: Yield: 32%; 
1
H NMR (400 MHz, 
CDCl3) δ 8.34 (s, 1H), 7.35–7.22 (m, 7H), 6.99–6.97 
(m, 2H), 5.75 (m, 1H), 5.35 (s, 1H), 5.35–5.28 (m, 
2H), 5.24 (s, 1H), 4.13–4.10 (m, 2H), 4.00 (m, 2H), 
3.82 (d, J = 5.2 Hz, 3H), 3.62–3.60 (m, 1H), 2.94–2.91 (m, 1H), 2.89 (d, J = 
4.8 Hz, 3H), 2.84 (d, J = 4.8 Hz, 1H), 1.85 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 179.9, 177.3, 159.3, 158.1, 156.7, 140.4, 134.0, 133.9, 129.3, 129.1, 
128.9, 128.7, 127.9, 127.6, 127.2, 126.7, 118.3, 116.4, 114.8, 114.5, 114.4, 
114.1, 103.3, 76.7, 55.5, 40.4, 35.5, 29.7, 28.29, 28.26; HRMS (FAB+) m/z 
calcd for C31H31N5O3 [M+H]
+
: 522.2505; Found: 522.2502. 
Compound 7f: Yield: 32%; 
1
H NMR (400 MHz, 
CDCl3) δ 8.32 (s, 1H), 7.40–7.16 (m, 4H), 6.98–
6.95 (m, 2H), 6.86–6.84 (m, 2H), 5.74–5.73 (m, 
1H), 5.32 (d, J = 6.0 Hz, 1H), 5.28–5.26 (m, 2H), 
5.23 (s, 1H), 4.05–4.00 (m, 2H), 3.96–3.92 (m, 2H), 3.79 (s, 3H), 3.77 (s, 
3H), 3.61–3.55 (m, 1H), 2.95–2.89 (m, 1H), 2.87 (d, J = 4.8 Hz, 3H), 2.83 (d, 
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J = 4.8 Hz, 1H), 1.83 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 177.7, 177.2, 
168.2, 159.8, 159.3, 156.6, 151.1, 134.0, 132.6, 128.5, 128.0, 127.9, 118.1, 
114.46, 114.40, 60.8, 55.5, 55. 2, 52.6, 40.4, 35.5, 31.9, 31.4, 30.2, 29.7, 28.2, 
22.6; HRMS (FAB+) m/z calcd for C32H33N5O4 [M+H]
+
: 552.2611; Found: 
552.2605. 
3.1.9. Principal Component Analysis (PCA) Data 
3.1.9.1. Eigenvalues of the covariance matrix 
Eigenvalues of the covariance matrix 
 Eigenvalue Difference Proportion Cumulative 
Prin 1 1599.23729 1030.25068 0.6138 0.6138 
Prin 2 568.98661 265.65905 0.2184 0.8321 
Prin 3 303.32756 199.55242 0.1164 0.9485 
3.1.9.2. Eigenvectors in principal component analysis 
Eigenvectors 
 Prin 1 Prin 2 Prin 3 
Ring Energy 0.304456 0.182719 0.262972 
Molecular weight 0.370201 –0.062337 0.347968 
Topological PSA 0.454293 0.212850 –0.024271 
2D VDW surface 0.405094 –0.093542 0.144375 
2D VDW volume 0.394177 –0.145550 0.166564 
Fraction of 2D VSA hydrophobic –0.056418 –0.092711 0.084747 
Fraction of 2D VSA polar 0.162504 0.308346 –0.347758 
Fraction of 2D VSA Hbond donor –0.245592 0.817384 0.216717 
Fraction of 2D VSA Hbond 
acceptor 
0.389214 0.254489 –0.599958 





3.2. Experimental section for chapter 2 
3.2.1. General synthetic procedure for intermediate compounds 2’a-c 
 
A solution of p-tolylhydrazine hydrochloride (10g, 0.063 mol), TEA (8.8 ml, 0.063 
mol) in THF (200 ml) was added and a solution of isocyanate (1.0 eqv) in THF was 
added. After stirring at room temperature for 7 hr until starting material were 
consumed, the reaction mixture was quenched with deionized water. The resultant 
was extracted with ethyl acetate (EA) twice and dried with anhydrous Na2SO4(s). 
After the solvent was removed under the reduced pressure, the residue was purified 
by silica-gel flash column chromatography to obtain 2’a-c 
 
Compound 2’a: Yield: 94%; 
1
H NMR (500 
MHz, DMSO-d6) δ 7.75 (s, 1H), 7.41 (s, 1H), 
6.96 (d, 2H, J=8Hz), 6.61 (d, 2H, Z=8.5 Hz),  
6.53 (s, 1H), 5.74-5.79 (m, 1H), 4.95-5.05 (dd, 2H, J=17 Hz, J=10.5 Hz), 3.63 (s, 
2H), 2.16 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 159.5, 147.6, 137.2, 
129.6(2C), 127.8, 114.5, 112.9(2C), 41.6, 20.6; LRMS (ESI) m/z calcd for 
C11H15N3O [M+1]+:206.12; Found: 206.04.  
 
Compound 2’b: Yield: 91%; 
1
H NMR (500 
MHz, DMSO-d6) δ 7.83 (s, 1H), 7.46 (s, 1H), 
7.26-7.28 (m, 3H), 7.18-7.23 (m, 2H), 7.01 (s, 
1H), 6.97 (d, J=8.5  
 
42 
Hz, 2H), 6.64 (d, J=8 Hz, 2H), 4.22 (d, J=6 Hz, 2H), 2.17 (s, 3H); 13C NMR (100 
MHz, DMSO-d6) δ 159.8, 147.6, 141.5, 129.6(2C), 128.5(2C), 127.8, 127.4(2C) 
126.9, 112.9(2C), 42.9, 20.6; LRMS (ESI) m/z calcd for C15H17N3O 
[M+1]+:256.14; Found: 256.02. 
 
Compound 2’c: Yield: 88%; 
1
H NMR (500 
MHz, DMSO-d6) δ 8.75 (s, 1H), 8.15 (s, 1H), 
7.55 (t, J=3 Hz, J=5.5 Hz, 2H), 7.54 (s, 1H), 
7.04 (t, J=9 Hz,  
J=8.5 Hz, 2H), 6.98 (d, J=8 Hz, 2H), 6.68 (d, J=8.5 Hz, 2H), 2.17 (s, 3H); 
13
C NMR 
(100 MHz, DMSO-d6) δ 168.6, 155.9, 147.4, 130.2(2C), 120.3(2C), 116.1(2C), 
113.8(2C), 58.9, 43.9, 21.1; LRMS (ESI) m/z calcd for C14H14FN3O 
[M+1]+:260.11; Found: 260.00. 
          
3.2.2. General synthetic procedure for intermediate compounds 3’a-c 
 
A 500 ml round-bottom-flash was fitted with a glass stopper and reflux condenser. A 
suspension of 2’a-c (10g, 1eqv) in 220ml of DMF was added to the flask and then 
KHCO3 (1 eq), t-Butylbromoacetate (2 eq) was added and stirred at 80
0
C for 24h 
until starting material were consumed. The reaction mixture was filtered and 
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extracted with ethyl acetate (EA) (200ml X 3). The organic solution was washed 
with Brine (200ml X 3), evaporated and the residue was purified by silica-gel flash 
column chromatography to obtain 3’a-c  
 
 
Compound 3’a: Yield: 68%; 
1
H NMR (500 
MHz, CDCl3) δ 7.07 (d, 2H, J=8 Hz), 6.74 (d, 
2H, J=2 Hz), 6.64 (s, 1H), 6.28 (t, 1H), 5.78-
5.84 (m, 1H), 5.03-5.12 (m, 2H), 4.22 (d, 1H, 
J=18 Hz), 3.97 (d, 1H 
,J=17.5 Hz), 3.83-3.87 (m, 2H), 2.26 (s, 3H), 1.403 (s, 9H); 
13
C NMR (100 MHz, 
CDCl3) δ 169.2, 158.1, 145.9, 135.0, 130.4, 129.9(2C), 115.4, 113.3(2C), 82.8, 





Compound 3’b: Yield: 70%; 
1
H NMR (500 
MHz, CDCl3) δ 7.9 (s, 1H), 7.25 (d, J=8.5 Hz, 
2H), 7.22 (t, J=3 Hz, J=14.5 Hz, 1H), 7.18 (t, 
J=4.5 Hz, J=5.5 Hz, 2H), 7.01 (d, J=10.5 Hz, 
2H), 6.63 (d, J=11 Hz, 2H),  
3.32 (s, 3H), 1.38 (t, J=4.5 Hz, J=10 Hz, 9H); 
13
C NMR (100 MHz, CDCl3) δ 
170.2, 170.2, 158.5, 146.9, 140.8, 129.8(2C), 128.6(2C), 127.2(2C), 126.9, 113(2C), 
81.9, 57.9, 42.9, 28.2(3C), 20.4; LRMS (ESI) m/z calcd for C21H27N3O3 [M+1]
+
: 




Compound 3’c: Yield: 59%; 
1
H NMR (500 
MHz, CDCl3) δ 8.61 (s, 1H), 7.42 (d, J=5, 2H), 
7.30 (d, J=5, 2H), 7.13(d, J=5, 2H), 7.00(d, 
J=10), 3.96 (s, 2H), 2.31 (s, 3H), 1.49 (s, 9H); 
13
C NMR (100 MHz,  
CDCl3) δ 173.2, 172.8, 163.6, 156.6, 140.3, 130.6(2C), 116.4(2C), 116.1(2C), 
113.4(2C), 112.2, 75.4, 65.4, 28.8, 20.8; LRMS (ESI) m/z calcd for C20H24FN3O3 
[M+1]
+
: 374.18; Found: 374.03. 
 
3.2.3. General synthetic procedure for intermediate compounds 4’a-c 
 
A 500 ml round-bottom-flash was fitted with a glass stopper and reflux condenser. A 
suspension of 3’a-c (10g) in HCl (20ml, 4N solution in 1,4-Dioxane) was added to 
the flask and stirred at room temp for overnight until starting material were 
consumed. The reaction mixture was concentrated completely by rotary evaporation 
at 40
0
C at aspirator vacuum. The saturated aq. NaHCO3 solution was added (to pH 
10) and the aqueous layer was washed with ethyl acetate (EA) (200ml X 3). Conc. 
HCl was added dropwise (to pH 2-3). The mixture was extracted with ethyl acetate 
(EA) (200ml X 3), and the organic layer was dried over Na2SO4 and evaporated. 
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Compound 4’a: Yield: 78%; 
1
H NMR (500 
MHz, DMSO-d6) δ 12.55 (s, 1H), 8.01 (s, 1H), 
7.02 (d, 2H, J=7.5 Hz), 6.61 (d, 2H, J=8 Hz), 
5.75-5.80 (m, 1H), 5.06 (d, 1H, J=17 Hz), 4.98 
(d, 1H, J=10.5 Hz), 4.15  
(d, 2H, J=35.5 Hz), 3.66 (s, 2H), 3.41 (s, 1H), 2.48 (s, 3H); 
13
C NMR (100 MHz, 
DMSO-d6) δ 172.8, 158.7, 146.7, 136.6(2C), 129.8(2C), 114.9, 112.7, 56.3, 41.8, 
20.4; LRMS (ESI) m/z calcd for C13H17N3O3 [M+1]+:264.13; Found: 264.08. 
 
 
Compound 4’b: Yield: 80%; 
1
H NMR (500 
MHz, DMSO-d6) δ 12.55 (s, 1H), 8.02 (s, 1H), 
7.38 (s, 1H), 7.27 (t, J=8 Hz, J=7 Hz, 3H), 7.21 
(d, J=6.5 Hz, 2H), 7.19 (t, J=5.5 Hz, J=7.5 Hz, 
2H), 7.02 (d, J=8.5 Hz,  
2H), 6.63 (d, J=8.5 Hz, 2H), 4.24 (d, J=6 Hz, 2H), 3.34 (s, 2H), 2.19 (s, 3H); 
13
C 
NMR (100 MHz, DMSO-d6) δ 172.7, 158.9, 146.8, 140.7, 129.8(2C), 128.6(2C), 
128.1, 127.3(2C), 127.1 (2C), 112.8, 56.19, 43.1, 20.4; LRMS (ESI) m/z calcd for 
C17H19N3O3 [M+1]
+





Compound 4’c: Yield: 75%; 
1
H NMR (500 
MHz, DMSO-d6) δ 12.85 (s, 1H), 9.27 (s, H), 
8.42 (s, 1H), 7.48 (d, J=5 Hz, 2H), 7.09 (d, J=10 
Hz, 2H),  7.05 (d, J=10 Hz, 2H), 6.70 (d, J=10 
Hz, 2H), 4.09 (s, 2H),  
2.19 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 173.2, 172.8, 130.6, 129.3, 121.0, 
119.7, 116.4(2C), 116.3(2C), 116.2, 115.1(2C), 114.9(2C), 113.7, 54.0, 20.8; LRMS 
(ESI) m/z calcd for C16H16N3O3 [M+1]
+
:318.12; Found: 317.93. 




H NMR (500 MHz, 
CDCl3) δ 7.23-7.36 (m, 9H), 7.12 (d, J=8 Hz, 2H), 
6.84 (d, J=8.5 Hz, 2H), 6.65 (dd, J=4 Hz, J=7.5 Hz, 
J=4 Hz, 1H), 6.60 (t, J=6 Hz, J=6 Hz, 1H), 5.17 (t, 
J=4 Hz, J=6 Hz, 1H), 4.54 (m, 2H), 4.22 (d, J=17 
Hz, 1H), 3.90 (d, J=17.5 Hz  
, 1H), 3.76 (dd, J=13.5 Hz, J=5 Hz, J=13 Hz, 2H), 3.34 (m, 1H), 3.16 (m, 4H), 3.05 
(m, 1H), 2.31 (s, 3H), 1.27 (m, 2H), 1.20 (m, 2H), 0.86 (t, J=7.5 Hz, J=7 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 164.9, 162.9, 156.2, 132.8, 131.1, 130.9, 129.8, 
129.4(2C), 129.1(2C), 129.1(2C), 128.6(2C), 128.2(2C), 128.0, 127.9, 127.6, 127.0, 
126.4, 116.0, 114.7(2C), 62.2, 54.3, 54.1, 50.0, 47.0, 26.9, 13.8; LRMS (ESI) m/z 
calcd for C32H36ClN5O3 [M+1]
+






H NMR (500 MHz, 
CDCl3) δ 7.27 (m, 5H), 7.09 (t, J=3.5 Hz, J=4 Hz, 
1H), 7.05 (d, J=8.5 Hz, 2H), 6.75 (d, J=8.5 Hz, 
2H), 6.38 (dd, J=6.5 Hz, J=2 Hz, J=6.5 Hz, 1H), 
6.13 (t, J=6 Hz, J=6 Hz,  
1H), 5.83 (m, 1H), 5.14 (dd, J=7 Hz, J=5 Hz, J=5 Hz, 2H), 4.67 (d, J=15 Hz,1H), 
4.49 (s, 1H), 4.28 (d, J=17 Hz, 1H), 4.20 (d, J=14.5 Hz, 1H), 4.02 (d, J=17 Hz, 1H), 
3.95 (m, 1H), 3.87 (m, 1H), 3.065 (t, J=6.5 Hz, J=2 Hz, 2H), 2.9 (s, 3H), 2.23 (m, 
1H), 1.61 (m, 2H), 1.39 (m, 2H), 1.11 (d, J=7 Hz, 3H), 0.97 (t, J=7.5 Hz, J=7 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 162.6, 161.7, 156.5, 152.8, 143.7, 135.7, 
131.1(2C), 129.3, 128.7(2C), 128.2(2C), 127.4, 114.5(2C), 113.5, 85.2 60.6, 59.9, 
59.1, 50.5, 48.6, 42.3, 38.7, 26.5, 15.8, 10.1; LRMS (ESI) m/z calcd for C28H35N5O3 
[M+1]
+
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     T_P9.RAW 
     RT: 0.00 - 20.00 
     Number of detected peaks: 4 
    Apex RT Start RT End RT Area %Area Height %Height 
7.26 7.22 7.28 79896.75 2.93 24412 5.62 
8.3 8.24 8.34 126658 4.63 28678.89 6.6 
8.63 8.48 8.84 2462377 90.11 361253.9 83.2 






























Crude LC  
 
LC after fast purify 
 
PEAK LIST 
     TX4.RAW 
      RT: 0.00 - 20.00 
     Number of detected peaks: 2 
    Apex RT Start RT End RT Area %Area Height %Height 
7.66 7.6 7.7 273548.8 3.52 59534.75 6.29 





































2.3. List of nine Fmoc Amino acids (R4) and three amines (R3) used for 
library construction  






2.4. PDA based LC/MS analysis data for library compounds 
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